Structured Guidance for Care Delivery May Result in Better Counselling for Patients With Breast Cancer

Article

Nurse Navigator Janeen Bazan, RN, OCN, BSN, talks about the 4R Care Sequence® and its impact on the care of patients with breast cancer at the 2021 Oncology Nursing Society Annual Congress.

According to a poster presentation at the recent 2021 Oncology Nursing Society (ONS) Annual Congress, breast cancer care may benefit from guidance in a new care delivery model.

The 4R Care Sequence® is a one-page, multimodality, personalized care project plan that is used by multidisciplinary teams to plan and deliver care. The 4 Rs in the title represent the right information, care, patient, and time. It incorporates recommendations for patient-centric care pathway plans from the Institute of Medicine, Medicare’s Oncology Care Model and National Comprehensive Cancer Network guidelines, which include multi-modality planning from diagnosis to survivorship that specifies the clinical team, identification of therapy, and adverse effects and supportive care.

“The 4R model provides a roadmap for the patient and also for the patient’s care team,” said Janeen Bazan, RN, OCN, BSN, lead author of the poster and an oncology nurse navigator from Advocate Sherman Hospital, during the presentation. “It’s very helpful in time management for the patient.”

To understand how the 4R Care Sequence® plans impacted care, investigators surveyed 77 patients with stage 0 to 3 breast cancer from September 2019 to August 2020 at Advocate Sherman Hospital. Of the patients, 28 received 4R Care Sequences® and 49 received a baseline control model.

A survey given to all patients asked whether or not the patients’ care provider instructed them to do certain activities. The investigators found that all patients who received the 4R Care Sequences® were more likely to have been counseled in 8 areas:

  • Getting an immunization (flu, pneumonia, shingles) before starting cancer treatment (52% of baseline cohort, 70% of 4R cohort)
  • Seeing a dentist before starting cancer treatment (13% of baseline cohort, 33% of 4R cohort)
  • Getting a genetic counseling appointment before surgical decision (39% of baseline cohort, 44% of 4R cohort)
  • Managing weight if over or under weight (16% of baseline cohort, 26% of 4R cohort)
  • Getting a nutritionist consult about how to eat during cancer treatment (15% of baseline cohort, 26% of 4R cohort)
  • Getting emotional support (46% of baseline cohort, 52% of 4R cohort)
  • Keeping up appointments with primary care for routine care (67% of baseline cohort, 75% of 4R cohort)
  • Caring for a chronic disease (43% of baseline cohort, 46% of 4R cohort)

Early results showed that the use of the 4R Care Sequences® improved the referrals of recommended breast cancer care. Due to the small sample size, Bazan reported that the results are not statistically significant, however, the trend is still encouraging. The researchers’ plan to continue using 4R Care Sequences, collecting patient surveys and assessing their impact.

“I’m very excited to look at our next data and share with other programs, and hopefully bring in other cancer types,” Bazan said.

Reference

Bazan J. Early results: Impact of 4R (Right Info / Care / Patient / Time) care sequence plans, provided to patients by oncology nurses, on timing and sequence of guideline recommended care. Presented at: Oncology Nursing Society 46th Annual Congress; April 20, 22, 27, and 29, 2021. ePoster 1567. Accessed May 5, 2021. https://bit.ly/3eXEb0n

Recent Videos
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content